Scienture Holdings, Inc.今日发布公告，正式启动Rezenopy™的商业化上市，并已完成首批采购订单的履约交付。Rezenopy™作为美国食品药品监督管理局（FDA）批准的最高剂量纳洛酮鼻喷雾剂，标志着公司在阿片类药物过量逆转领域迈出了关键一步。
Scienture Holdings, Inc.今日发布公告，正式启动Rezenopy™的商业化上市，并已完成首批采购订单的履约交付。Rezenopy™作为美国食品药品监督管理局（FDA）批准的最高剂量纳洛酮鼻喷雾剂，标志着公司在阿片类药物过量逆转领域迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.